

GSK's Clinical Development Plan for DuchenneGSK has released comprehensive details their four controlled clinical studies to evaluate the effect of the investigational medicine GSK2402968 (GSK’968), formerly known as PRO051, in boys with Duchenne, who have a dystrophin gene mutation amenable to an exon 51 skip. Prosensa Raises €23 Million in New Equity FinancingProsensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised €23 million in new equity financing. This new investment gives additional stability to the company and allows Prosensa to keep advancing the Duchenne programs as fast as possible. Important Advocacy Webinar: PDUFA ReauthorizationPDUFA allows for the FDA to collects fees from drug manufacturers to, in turn, improve and expedite the approval process for drugs. The fees collected are used by the FDA to increase efficiency and timeliness with review of license application and increase their medical and scientific staff capability. Learn more about important legislation that affects the Duchenne community by joining us on this week's webinar (Wednesday, January 25th at 1pm Eastern). PPMD Awards Stanley Froehner, PhD, $132,322 GrantPPMD recently announced that it will award University of Washington’s Dr. Stanley Froehner a grant in the sum of $132,322 to continue his work with sildenafil (Viagra) and prednisone, as PDE5 inhibitors like sildenafil are brought to human clinical trials. According to Dr. Froehner’s research, studies of sildenafil, an FDA drug that amplifies the nNOS signaling pathway, demonstrate a marked improvement in heart and diaphragm function in the mdx mouse. In preparation for expanded clinical trials in Duchenne patients, his team will determine in mdx mice if sildenafil and prednisone have additive effects, or if prednisone can interfere with the positive effects of sildenafil. Since steroids are standard care in Duchenne, investigators want to understand how drugs will act when used in combination with steroids.
NORD's letter to Congressman StearnsThe National Organization for Rare Disorders (NORD) believes that there are regulatory and legislative alternatives to the recent "Unlocking Lifesaving Treatments for Rare Diseases Act" (ULTRA) proposal that can more quickly advance the development of new drugs for rare diseases.
The January eNewsletter is here!With the New Year, we are excited to bring you a revamped newsletter that gives you the inside scoop on the latest happenings in Duchenne research, advocacy, care, and the community. We will also bring you a new monthly feature, My Voice, featuring someone special living with Duchenne. |
PPMD Pres Pat Furlong & CO FACES Coordinator Ivy Scherbarth co-blog about learning from our patient community. January 11, 2011 | Read More ![]()
|
© 2010 Parent Project Muscular Dystrophy | 800-714-5437 | info@parentprojectmd.org | Media | Site Map | Privacy Policy | Designed by Big Duck | EIN 31-1405490
![]() |
![]() |